Skip Repetitive Navigation
Substance Abuse & Mental Health Services Administration
Search SAMHSA
SAMHSA Home
MFP Coordinating Center
Resources
Applying for a Fellowship
Directory of Fellows
Contact Us
My Account
Login
Search by Keyword
Keyword
:
MFPCC Topic Area
:
Select One
African American Behavioral Health
Asian American and Pacific Islander Behavioral Health
Behavioral Health Evidence-Based Practices
Criminal Justice
Cultural Competence
Employment Information
Federal Government
Health Research Data
Integrated Care
Latino/Hispanic American Behavioral Health
LGBTQ Behavioral Health
Mental Health Treatment and Support Services
Other Behavioral Health Information Sources
Peer Advocacy and Community Recovery
Pharmacotherapy
Recovery-Oriented Research and Practice
Research and Training
Serving Children and Youth
Serving Diverse and Minority Populations
Substance Use and Addictions
Underserved Communities
Writing Guides
SAMHSA's Strategic Initiatives
:
Select One
Prevention of Substance Abuse and Mental Illness
Health Care and Health Systems Integration
Trauma and Justice
Recovery Support
Health Information Technology
Workforce Development
Explore By Profession
Addiction Counseling
Counseling
Marriage & Family Therapy
Nursing
Peer Support
Psychiatry
Psychology
Social Work
Quick Links
MFP Grantees
Enews
Webinars
Find us on LinkedIn
Provide Feedback
Suggest a Resource
Search Results: 1 Items Under the Contributor 'Stroup et al '
Sort By:
Select from Below
Title
Author
Contribution Date
Filter By:
Show All
Article
Research
Clinical tools
Personal stories
Outcome tools
Practice description
Books
Training material
Curricula
Video
Web site
Program description
Webinar
Enews
Event Announcements
Calendar Events
Other
A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
[PDF-1103685KB]
By:
Stroup et al
|
9/30/2011 12:00:00 AM
|
Content Types: Article, Research
Objective: The authors conducted a multisite randomized controlled trial examining the strategy of switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk factors for cardiovascular disease. Conclusions: S
[
View this item
]